Predictive Biosciences Appoints Dr. Angelo De Marzo to Leadership Team

LEXINGTON, Mass.--(BUSINESS WIRE)-- Predictive Biosciences, a leading provider of novel molecular diagnostic tests, has announced the appointment of Dr. Angelo M. De Marzo as Chief Medical Officer.

Angelo M. De Marzo, M.D., Ph.D., comes to Predictive Biosciences with an extensive background in prostate cancer research and urological pathology practice. Dr. De Marzo has been a faculty member at The Johns Hopkins University (JHU) School of Medicine since 1998, most recently as Professor of Pathology, Urology, and Oncology; Director of the Pathology Core for the Specialized Program of Research Excellence (SPORE) in prostate cancer; Associate Director of Pathology Cancer Research at the Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins; and Director of the Tissue Microarray Core (TMA) Facility at the SKCCC. His laboratory has focused both on understanding the molecular pathology of prostate cancer, as well as, clinical and translational research studies to analytically validate and interrogate biomarker expression in clinical pathology specimens. As leader of the immunohistochemistry core in the prostate cancer SPORE and the TMA core lab at JHU, his group developed open source software tools to facilitate high throughput TMA-based biomarker validation studies. Dr. De Marzo has also collaborated with a number of investigators at JHU and elsewhere to develop predictive biomarkers for prostate cancer. He received his M.D. and Ph.D. in experimental pathology from the University of Colorado Health Sciences Center and completed a research fellowship at The Brady Urological Institute at JHU.

"I am delighted to join Predictive Biosciences and contribute to the development of its novel non-invasive molecular diagnostics technologies," said Dr. De Marzo. "The Company’s approach of providing clinically actionable information through “molecular triage” is an exciting development in the emerging field of personalized medicine that could significantly improve the care of cancer patients."

“Angelo is a great addition to our management team," said Marc Schneebaum, President and CEO of Predictive Biosciences. "His distinguished reputation in the pathology and urological oncology communities, and his extensive clinical research experience, will substantially enhance our technology development and commercial strategies and operations. His focus on developing new insights into the molecular pathology of cancer should also help shape our product offerings for optimal utility to physicians and their patients."

About Predictive Biosciences

Predictive Biosciences develops novel molecular diagnostic cancer assays and provides anatomic pathology services for urology-based practices. Leveraging a portfolio of patented biomarkers and clinical approaches, the company is building a unique portfolio of assays for cancer management, first targeted at bladder and prostate cancer. For additional information, please visit www.predictivebiosci.com.



CONTACT:

Predictive Biosciences
Sharon Martin, 781-402-1780 x246
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Oncology

MEDIA:

Logo
 Logo

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.